Abstract 257: Pilot Study of the Safety and Feasibility of the Treatment of Paclitaxel Associated to a Cholesterol-Rich Nanoemulsion in Patients With Aortic Atherosclerotic Disease
| العنوان: | Abstract 257: Pilot Study of the Safety and Feasibility of the Treatment of Paclitaxel Associated to a Cholesterol-Rich Nanoemulsion in Patients With Aortic Atherosclerotic Disease |
|---|---|
| المؤلفون: | Raul C Maranhao, Afonso A Shiozaki, Tiago Senra, Aleksandra T Morikawa, Debora F Deus, Antonio T Paladino-Filho, Ibraim M Pinto |
| المصدر: | Arteriosclerosis, Thrombosis, and Vascular Biology. 35 |
| بيانات النشر: | Ovid Technologies (Wolters Kluwer Health), 2015. |
| سنة النشر: | 2015 |
| مصطلحات موضوعية: | Cardiology and Cardiovascular Medicine |
| الوصف: | Previously, we showed that the toxicity of chemotherapeutic agents used in cancer treatment can be drastically reduced by association to nanoemulsions (LDE) that mimic the lipid composition of low-density lipoprotein (LDL), without loss of pharmacological action. Injected into the circulation, LDE concentrates associated drugs, such as the anti-proliferative agent paclitaxel, in neoplastic tissues and in atherosclerotic lesions. In rabbits with atherosclerosis lesions were reduced by 65% by LDE-paclitaxel treatment. Tolerability and safety of high dose LDE-paclitaxel was shown in several patients with advanced cancers. Based on those findings, this pilot study was designed to test, in 9 aged patients with extensive aortic atherosclerosis, LDE-paclitaxel at 175 mg/m2 body surface dose (I.V., 3/3 weeks for 6 cycles). All were under statin treatment that was not discontinued during the 18-week treatment period. No observable clinical or laboratorial toxicity was observed. One death occurred but was unrelated with treatment toxicity. Images acquired by Multiple Detector Computer Tomography Angiography (64-slice scanner) taken before and at 2-3 month after the treatment end showed that the mean volume of the aortic artery wall was clearly reduced in 4 of the 8 patients, while in 3 it remained unchanged and in one it clearly increased. Therefore, the treatment was tolerable for patients with cardiovascular disease and these results encourage large, placebo-controlled clinical studies to ascertain the ability of LDE-paclitaxel to reduce atherosclerotic lesions. |
| تدمد: | 1524-4636 1079-5642 |
| DOI: | 10.1161/atvb.35.suppl_1.257 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::4f79ba549d3f39a5b6b81a537b4a830b https://doi.org/10.1161/atvb.35.suppl_1.257 |
| رقم الانضمام: | edsair.doi...........4f79ba549d3f39a5b6b81a537b4a830b |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15244636 10795642 |
|---|---|
| DOI: | 10.1161/atvb.35.suppl_1.257 |